Immunodiagnostics and Immunotherapy Possibilities for Prostate Cancer

  • Heide SchattenEmail author
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 1126)


Despite significant progress in early detection and improved treatment modalities prostate cancer remains the second leading cause of cancer death in American men which results in about 30,000 deaths per year in the USA. An aggressive phenotype leading to 2.58% risk of dying from prostate cancer still exists and immunotherapy has offered new possibilities to treat metastatic prostate cancer that cannot be treated by other modalities. Cancer immunotherapy is a rapidly growing field of research aimed at identifying biomarkers in immunodiagnosis and to develop new therapies by enabling the immune system to detect and destroy cancer cells. Immunotherapy falls into three different broad categories which are checkpoint inhibitors, cytokines, and vaccine immunotherapy. While immunotherapy to treat prostate cancer is still limited progress has been made; for treatment of advanced prostate cancer sipuleucel-T has been administered to patients in personalized doses to destroy prostate cancer cells which is promising and invites further research to determine immunotherapies for advanced prostate cancer. Antibody-based targeted immunotherapy and dendritic-cell-based vaccination are among the therapies that are currently being evaluated as promising approaches to treat prostate cancer. Combination immunotherapies include prostate cancer vaccines and radiotherapy for castration resistant prostate cancer. Microbial vectors for prostate cancer immunotherapy have been developed and bacterial strains have been engineered to express cancer-specific antigens, cytokines, and prodrug-converting cytokines. These approaches are addressed in the present review.


Prostate cancer Diagnosis Immunotherapy Metastasis 


  1. 1.
    Duensing S, Munger K (2003) Centrosome abnormalities and genomic instability induced by human papillomavirus oncoproteins. Prog Cell Cycle Res 5:383–391PubMedGoogle Scholar
  2. 2.
    Duensing S, Lee LY, Duensing A, Basile J, Piboonniyom S, Gonzalez S, Crum CP, Munger K (2000) The human papillomavirus type 16 E6 and E7 oncoproteins cooperate to induce mitotic defects and genomic instability by uncoupling centrosome duplication from the cell division cycle. Proc Natl Acad Sci U S A 97:10002–10007CrossRefGoogle Scholar
  3. 3.
    Korzeniewski N, Duensing S (2012) Disruption of centrosome duplication control and induction of mitotic instability by the high-risk human papillomavirus oncoproteins E6 and E7. In: Schatten H (ed) The centrosome, Chap 12. Springer, New York, NYGoogle Scholar
  4. 4.
    Schatten H (2013) The impact of centrosome abnormalities on breast cancer development and progression with a focus on targeting centrosomes for breast cancer therapy. In: Schatten H (ed) Cell and molecular biology of breast cancer. Springer, New York, NYCrossRefGoogle Scholar
  5. 5.
    Kadota K, Nitadori J, Ujiie H, Buitrago DH, Woo KM, Sima CS, Travis WD, Jones DR, Adusumilli PS (2015) Prognostic impact of immune microenvironment in lung squamous cell carcinoma: tumor-infiltrating CD10+ neutrophil/CD20+ lymphocyte ratio as an independent prognostic factor. J Thorac Oncol 10:1301–1310. CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Dahlin AM, Henriksson ML, Van Guelpen B, Stenling R, Oberg A, Rutegård J, Palmqvist R (2011) Colorectal cancer prognosis depends on T-cell infiltration and molecular characteristics of the tumor. Mod Pathol 24:671–682. CrossRefPubMedGoogle Scholar
  7. 7.
    Adams S, Gray RJ, Demaria S, Goldstein L, Perez EA, Shulman LN, Martino S, Wang M, Jones VE, Saphner TJ, Wolff AC, Wood WC, Davidson NE et al (2014) Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol 32:2959–2966. CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Karpathiou G, Monaya A, Forest F, Froudarakis M, Casteillo F, Dumollard JM, Prades JM, Peoc’h M (2016) P16 and p53 expression status in head and neck squamous cell carcinoma: a correlation with histologic, histoprognostic and clinical parameters. Pathology 48:341–348. CrossRefPubMedGoogle Scholar
  9. 9.
    Karpathiou G, Giroult J, Forest F, Fournel P, Monaya A, Froudarakis M, Dumollard J, Prades J, Gavid M, Peoc’h M (2016) Clinical and histological predictive factors of response to induction chemotherapy in head and neck squamous cell carcinoma. Am J Clin Pathol.
  10. 10.
    Sullivan RJ, Atkins MB, Kirkwood JM, Agarwala SS, Clark JI, Ernstoff MS, Fecher L, Gajewski TF, Gastman B, Lawson DH, Lutzky J, DF MD, Margolin KA, Mehnert JM, Pavlick AC, Richards JM, Rubin KM, Sharfman W, Silverstein S, Slingluff CL Jr, Sondak VK, Tarhini AA, Thompson JA, Urba WJ, White RL, Whitman ED, Hodi FS, Kaufman HL (2018) An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0. J ImmunoTher Cancer 6:44. CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Eggink LL, Roby KF, Cote R, Hoober JK (2018) An innovative immunotherapeutic strategy for ovarian cancer: CLEC10A and glycomimetic peptides. J ImmunoTher Cancer 6:28. CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Bajgain P, Tawinwung S, D’Elia L, Sukumaran S, Watanabe N, Hoyos V, Lulla P, Brenner MK, Leen AM, Vera JF (2018) CAR T cell therapy for breast cancer: harnessing the tumor milieu to drive T cell activation. J ImmunoTher Cancer 6:34. CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Chan IS, Bhatia S, Kaufman HL, Lipson EJ (2018) Immunotherapy for Merkel cell carcinoma: a turning point in patient care. J ImmunoTher Cancer 6:23. CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Hodi FS, O’Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711CrossRefGoogle Scholar
  15. 15.
    Topalian SL, Sznol M, McDermott DF et al (2014) Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 32:1020CrossRefGoogle Scholar
  16. 16.
    Topalian SL, Hodi FS, Brahmer JR et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443CrossRefGoogle Scholar
  17. 17.
    Tumeh PC, Harview CL, Yearley JH et al (2014) PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515:568CrossRefGoogle Scholar
  18. 18.
    Galon J, Costes A, Sanchez-Cabo F et al (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313:1960CrossRefGoogle Scholar
  19. 19.
    Naito Y, Saito K, Shiiba K et al (1998) CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 58:3491PubMedGoogle Scholar
  20. 20.
    Ropponen KM, Eskelinen MJ, Lipponen PK, Alhava E, Kosma VM (1997) Prognostic value of tumour-infiltrating lymphocytes (TILs) in colorectal cancer. J Pathol 182:318CrossRefGoogle Scholar
  21. 21.
    Harlin H, Meng Y, Peterson AC et al (2009) Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res 69:3077CrossRefGoogle Scholar
  22. 22.
    Salerno EP, Olson WC, McSkimming C, Shea S, Slingluff CL Jr (2014) T cells in the human metastatic melanoma microenvironment express site-specific homing receptors and retention integrins. Int J Cancer 134:563CrossRefGoogle Scholar
  23. 23.
    Spranger S (2016) Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment. Int Immunol 28(8):383–391. CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Wang Y, Abu-Sbeih H, Mao E, Ali N, Ali FS, Qiao W, Lum P, Raju G, Shuttlesworth G, Stroehlein J, Diab A (2018) Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson. J ImmunoTher Cancer 6:37. CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Schatten H (2018) Brief overview of prostate cancer statistics, grading, diagnosis and treatment strategies. In: Schatten H (ed) Cell and molecular biology of prostate cancer: updates, insights and new frontiers. Springer, New York, NYCrossRefGoogle Scholar
  26. 26.
    Howlader N, Noone AM, Krapcho M (eds), et al. (2015). SEER cancer statistics review, 1975–2012, National Cancer Institute: Bethesda, MD Accessed 5 May 2015.Google Scholar
  27. 27.
    Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62:10–29CrossRefGoogle Scholar
  28. 28.
    U.S. Cancer Statistics Working Group (2014) United States cancer statistics: 1999–2011 incidence and mortality web-based report. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute, Atlanta Available from: Accessed 5 May 2015Google Scholar
  29. 29.
    Karan D, Holzbeierlein JM, Van Veldhuizen P, Thrasher JB (2012) Cancer immunotherapy: a paradigm shift for prostate cancer treatment. Nat Rev Urol 9:376–385CrossRefGoogle Scholar
  30. 30.
    Robert G et al (2009) Inflammation in benign prostatic hyperplasia: a 282 patients’ immunohistochemical analysis. Prostate 69:1774–1780CrossRefGoogle Scholar
  31. 31.
    Sottnik JL, Zhang J, Macoska JA, Keller ET (2011) The PCa tumor microenvironment. Cancer Microenviron 4:283–297CrossRefGoogle Scholar
  32. 32.
    Theyer G et al (1992) Phenotypic characterization of infiltrating leukocytes in benign prostatic hyperplasia. Lab Invest 66:96–107PubMedGoogle Scholar
  33. 33.
    Dalgleish AG, Whelan MA (2006) Cancer vaccines as a therapeutic modality: the long trek. Cancer Immunol Immunother 55:1025–1032CrossRefGoogle Scholar
  34. 34.
    Dupont B (2002) Introduction: current concepts in immunity to human cancer and therapeutic antitumor vaccines. Immunol Rev 188:5–8CrossRefGoogle Scholar
  35. 35.
    Karan D, Krieg AM, Lubaroff DM (2007) Paradoxical enhancement of CD8 T cell-dependent anti-tumor protection despite reduced CD8 T cell responses with addition of a TLR9 agonist to a tumor vaccine. Int J Cancer 121:1520–1528CrossRefGoogle Scholar
  36. 36.
    Saenz-Badillos J, Amin SP, Granstein RD (2001) RNA as a tumor vaccine: a review of the literature. Exp Dermatol 10:143–154CrossRefGoogle Scholar
  37. 37.
    Schirrmacher V (1995) Tumor vaccine design: concepts, mechanisms, and efficacy testing. Int Arch Allergy Immunol 108:340–344CrossRefGoogle Scholar
  38. 38.
    Fong L, Small EJ (2007) Immunotherapy for prostate cancer. Curr Oncol Rep 9:226–233CrossRefGoogle Scholar
  39. 39.
    Minev BR, Guo F, Gueorguieva I, Kaiser HE (2002) Vaccines for immunotherapy of breast cancer and prostate cancer: new developments and comparative aspects. In Vivo 16:405–415PubMedGoogle Scholar
  40. 40.
    Simons JW, Sacks N (2006) Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy: the GVAX vaccine for prostate cancer. Urol Oncol 24:419–424CrossRefGoogle Scholar
  41. 41.
    US National Library of Medicine (2012) [online]. Randomized phase II trial of a DNA vaccine encoding prostatic acid phosphatase (pTVG-HP) versus GM-CSF adjuvant in patients with non-metastatic prostate cancer. US National Library of Medicine, Bethesda, MDGoogle Scholar
  42. 42.
    Chambers CA, Kuhns MS, Egen JG, Allison JP (2001) CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol 19:565–594CrossRefGoogle Scholar
  43. 43.
    May KF Jr, Gulley JL, Drake CG, Dranoff G, Kantoff PW (2011) Prostate cancer immunotherapy. Clin Cancer Res 17:5233–5238CrossRefGoogle Scholar
  44. 44.
    Sharma P, Wagner K, Wolchok JD, Allison JP (2011) Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer 11:805–812CrossRefGoogle Scholar
  45. 45.
    Small EJ et al (2007) A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res 13:1810–1815CrossRefGoogle Scholar
  46. 46.
    Thomas-Kaskel AK, Waller CF, Schultze-Seemann W, Veelken H (2007) Immunotherapy with dendritic cells for prostate cancer. Int J Cancer 121:467–473CrossRefGoogle Scholar
  47. 47.
    Kantoff PW et al (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363:411–422CrossRefGoogle Scholar
  48. 48.
    Bermudes D, Low KB, Pawelek J, Feng M, Belcourt M, Zheng LM, King I (2001) Tumour-selective Salmonella based cancer therapy. Biotechnol Genet Eng Rev 18:219–233CrossRefGoogle Scholar
  49. 49.
    Bermudes D, Zheng LM, King IC (2002) Live bacteria as anticancer agents and tumor-selective protein delivery vectors. Curr Opin Drug Discov Devel 5:194–199PubMedGoogle Scholar
  50. 50.
    Eisenstark A, Kazmierczak RA, Fea A, Khreis R, Newman D, Schatten H (2007) Development of Salmonella strains as cancer therapy agents and testing in tumor cell lines. In: Schatten H, Eisenstark A (eds) Methods in molecular biology, Salmonella protocols, vol 253. Humana, Totowa, NJ, pp 321–353Google Scholar
  51. 51.
    Forbes NS (2010) Engineering the perfect (bacterial) cancer therapy. Nat Rev Cancer 10(11):785–794CrossRefGoogle Scholar
  52. 52.
    Forbes NS, Munn LL, Fukumura D, Jain RK (2003) Sparse initial entrapment of systemically injected Salmonella typhimurium leads to heterogeneous accumulation within tumors. Cancer Res 63:5188–5193PubMedGoogle Scholar
  53. 53.
    Kazmierczak RA, Dino A, Eisenstark A, Schatten H (2013) New breast cancer treatment considerations – a brief review of the use of genetically modified (attenuated) bacteria as therapy for advanced and metastatic breast cancer. In: Schatten H (ed) Cell and molecular biology of breast cancer. Springer, New York, NYGoogle Scholar
  54. 54.
    Kazmierczak RA, Gentry B, Mumm T, Schatten H, Eisenstark A (2016) Salmonella bacterial monotherapy reduces autochthonous prostate tumor burden in the TRAMP mouse model. PLoS One 11(8):e0160926. PMID: 27504973 Free PMC ArticleCrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Low KB, Ittensohn M, Le T, Platt J, Sodi S, Amoss M, Ash O, Carmichael E, Chakraborty A, Fischer J, Lin SL, Luo X, Miller SI, Zheng L, King I, Pawelek JM, Bermudes D (1999) Lipid A mutant Salmonella with suppressed virulence and TNFα induction retain tumor targeting in vivo. Nat Biotechnol 17:37–41CrossRefGoogle Scholar
  56. 56.
    Pawelek JM, Low KB, Bermudes D (1997) Tumor targeted Salmonella as a novel anticancer vector. Cancer Res 57:4537–4544PubMedGoogle Scholar
  57. 57.
    Pawelek JM, Sodi S, Chakraborty AK, Platt JT, Miller S, Holden DW, Hensel M, Low KB (2002) Salmonella pathogenicity island-2 and anticancer activity in mice. Cancer Gene Ther 9:813–818CrossRefGoogle Scholar
  58. 58.
    Pawelek JM, Low KB, Bermudes D (2003) Bacteria as tumour-targeting vectors. Lancet Oncol 4:548–556CrossRefGoogle Scholar
  59. 59.
    Saltzman DA (2005) Cancer immunotherapy based on the killing of Salmonella typhimurium-infected tumour cells. Expert Opin Biol Ther 5:443–449CrossRefGoogle Scholar
  60. 60.
    Paterson Y, Guirnalda PD, Wood LM (2010) Listeria and Salmonella bacterial vectors of tumor-associated antigens for cancer immunotherapy. Semin Immunol 22:183–189CrossRefGoogle Scholar
  61. 61.
    Schatten H, Ripple M (2018) The impact of centrosome pathologies on prostate cancer development and progression. In: Schatten H (ed) Cell and molecular biology of prostate cancer: updates, insights and new frontiers. Springer, New York, NYCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  1. 1.Department of Veterinary PathobiologyUniversity of MissouriColumbiaUSA

Personalised recommendations